Document is current
Any future updates will be listed below
-
Authors
Scalambra, Laura
Ruzzi, Francesca https://orcid.org/0000-0001-9555-3166
Pittino, Olga Maria
Semprini, Maria Sofia
Cappello, Chiara
Angelicola, Stefania
Palladini, Arianna
Nanni, Patrizia
Goksøyr, Louise
Fougeroux, Cyrielle
Penichet, Manuel L.
Sander, Adam Frederik
Lollini, Pier-Luigi
- License Information
-
More Information
Article History
Received: 3 December 2024
Accepted: 9 January 2025
First Online: 30 January 2025
Declarations
:
: All in vivo experiments were performed according to Italian and European laws and were authorized by the Italian Ministry of Health (letter 714–2017-PR).
: Not applicable.
: L.G., C.F. and A.F.S. are listed as co-inventors on a patent application covering the Delivery of a cVLP-based modular vaccine platform in a nucleic acid platform (P5856PC00). Employees of AdaptVac (L.G., C.F. and A.F.S.), a company commercializing virus-like particle display technology and vaccine, including several patents.
